Zynerba Pharmaceuticals EBIT

The latest EBIT for ZYNE is $-39M as of June 2023. That compares with $-37M in the prior-year period — down 4.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Zynerba Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZYNE's EBIT moved from $-37M to $-39M — a 4.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zynerba Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ZYNE currently prints $-39M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Zynerba Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-39M for ZYNE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ZYNE's EBIT ($-39M), review year-over-year change from $-37M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.